The Scheduling of MDMA: A Pharmacist's Perspective
Journal of Psychoactive Drugs July 1, 1985 DOI: 10.1080/02791072.1985.10472337 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractA pharmacist argues against the emergency scheduling of MDMA (Ecstasy) as a Schedule I controlled substance, contending that the drug has legitimate therapeutic potential in psychotherapy and that its risks are not sufficiently understood to justify the most restrictive classification. The author reviews the pharmacology, clinical uses, and potential adverse effects of MDMA, and criticizes the scheduling process for lacking thorough scientific evaluation. The piece calls for more research and a more balanced regulatory approach that considers both the benefits and risks of the substance.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Citations | 26 |
| Key finding | Argues that MDMA's pharmacological properties and therapeutic promise do not justify Schedule I classification, which would impede research and clinical use. |
Abstract
(1985). The Scheduling of MDMA: A Pharmacist's Perspective. Journal of Psychoactive Drugs: Vol. 17, No. 3, pp. 167-171.